Customized Indomethacin-Induced Colitis Models

Indomethacin is an easy-to-administer, widely available, and clinically significant nonsteroidal anti-inflammatory drug (NSAID). Researchers have successfully developed a well-established indomethacin-induced rat model of inflammatory bowel disease (IBD). The lesions showed longitudinal ulceration, mainly on the mesenteric side of the distal small intestine, with varying degrees of inflammation and necrosis in all layers of the intestinal wall. This model is favored by researchers for its ease of induction and reproducibility.

Fig. 1. Glycomacropeptide ameliorates indomethacin-induced enteropathy in rats by modifying intestinal inflammation and oxidative stress. (Cervantes-García et al., 2020)

Our Indomethacin-Induced Colitis Models

Ace Therapeutics provides customized indomethacin-induced colitis models to help advance clients' IBD project. Our team of experts has extensive experience in IBD modeling and is dedicated to providing you with preclinical (efficacy and toxicity) data to support IBD drug development.

We model indomethacin-induced colitis for different species (e.g., mice, rats, etc.). Depending on the specific research needs of our clients, we can flexibly adjust the indomethacin administration (oral or subcutaneous), dosage, and administration time to induce different acute and chronic phases of IBD involving the small and large intestine.

Modeling Method	Male and female Sprague Dawley rats at 8 weeks of age are randomly assigned to either control or the indomethacin group. Indomethacin (7.5 mg/kg) is administered to the indomethacin group by subcutaneous injection once a day for two days, exactly 24 hours apart. Control rats receive saline/ethanol.
Features	Indomethacin injections can cause clinical symptoms and mechanisms similar to Crohn's disease (CD). Increased mucosal permeability, neutrophil infiltration, upregulation of inflammatory cytokines and small bowel lesions are observed in indomethacin-induced models. The disease peaks 2-3 days after indomethacin treatment and lasts up to 7 days.
Applications	Determine the role of various factors involved in the pathogenesis of intestinal inflammation. Provide a reliable, non-invasive model for drug screening. Study potential new therapies.

Preclinical Evaluation in Indomethacin-Induced Colitis Models

We assist clients in evaluating the therapeutic effects of drug candidates in indomethacin-induced colitis models.

Macroscopic measures such as colon length, colon weight, and colon/body weight ratio.
Histologic examination of the colon, including mucosal edema, ulceration, lymphocytic infiltration, etc.
PK/PD blood collection
Intestinal permeability assessment
Gut inflammation analysis
Gut oxidative damage analysis
Measurement of the number of myeloperoxidase (MPO) positive cells and MPO activity
Immunohistochemical analysis
Endoscopy
Mitochondrial assays, including measurements of intact mitochondrial respiration, reactive oxygen species (mtROS), activity of individual electron transport complexes, and antioxidant enzyme activity to assess mitochondrial function.

The Ace Therapeutics' team has extensive experience with indomethacin-induced colitis models and provides experimental protocol design, experimental operation and data analysis according to your specific needs. If you have any questions, please feel free to contact us, and we will do our best to provide you with high-quality services.

Reference

Cervantes-García, D., et al. (2020). Glycomacropeptide ameliorates indomethacin-induced enteropathy in rats by modifying intestinal inflammation and oxidative stress. Molecules, 25(10), 2351.

! For research use only, not intended for any clinical use.